Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Emicizumab In a Preterm Infant with Severe Hemophilia A – RPTH
First author of the article - Eman Hassan/LinkedIn
Apr 7, 2026, 15:54

Emicizumab In a Preterm Infant with Severe Hemophilia A – RPTH

RPTH Journal shared a post on LinkedIn about a recent article by Eman Hassan et al, adding:

”Emicizumab in a preterm infant with severe hemophilia A

Emicizumab has transformed prophylaxis in hemophilia A, but data in preterm and very low-birth-weight infants are virtually nonexistent.

What do you do when a baby is born at 30 weeks with severe HA and a high risk of intracranial hemorrhage?

A new case report in RPTH Journal describes exactly this scenario and the multidisciplinary decision-making behind it.

Key details:

  • Male infant born at 30+4 weeks to a known HA carrier
  • Severe HA confirmed; intracranial hemorrhage excluded on cranial ultrasound
  • Emicizumab prophylaxis initiated at just 26 hours of life
  • Loading phase completed and maintenance dosing achieved with no bleeding, thrombosis, or adverse events”

Title: Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use

Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani

Read the Full Article on RPTH Journal 

Emicizumab In a Preterm Infant with Severe Hemophilia A - RPTH

Stay updated on all scientific advances with Hemostasis Today.

Amna Ahmed bleeding disorders Charles Percy Eman Hassan Emicizumab Gillian Lowe Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today ICH infant Intracranial Hemorrhage Jayashree Motwani Medicine Neil V. Morgan rpth Will Lester
NewsFeed